IHS Chemical Week

Regions :: Western Europe :: Switzerland

Lonza and Eclipse Therapeutics Sign Development and Manufacturing Deal

12:06 AM MST | February 29, 2012 | Deepti Ramesh

Lonza says it has signed an agreement with private biotechnology company Eclipse Therapeutics (San Diego, CA) for the production of Eclipse’s novel cancer therapeutic antibody, ET-101, using Lonza’s light path development services. ET-101 is under investigation for the inhibition of the growth of cancer stem cells. Lonza will produce phase 1 clinical material at its development and manufacturing facility at Slough, U.K., under the deal. Cancer stem cells are a small subset of cells within a tumor that are thought to play a critical role in tumor...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa